Linda E. Klumpers
Linda E. Klumpers
Clinical Scientist
Verified email at chdr.nl
Title
Cited by
Cited by
Year
Brief treatment with the glucocorticoid receptor antagonist mifepristone normalises the corticosterone‐induced reduction of adult hippocampal neurogenesis
JL Mayer, L Klumpers, S Maslam, ER De Kloet, M Joels, PJ Lucassen
Journal of neuroendocrinology 18 (8), 629-631, 2006
1992006
Novel Δ9‐tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects
LE Klumpers, TL Beumer, JGC van Hasselt, A Lipplaa, LB Karger, ...
British journal of clinical pharmacology 74 (1), 42-53, 2012
712012
Manipulating brain connectivity with δ9-tetrahydrocannabinol: a pharmacological resting state FMRI study
LE Klumpers, DM Cole, N Khalili-Mahani, RP Soeter, ET te Beek, ...
Neuroimage 63 (3), 1701-1711, 2012
692012
Peripheral selectivity of the novel cannabinoid receptor antagonist TM 38837 in healthy subjects
LE Klumpers, M Fridberg, ML de Kam, PB Little, NO Jensen, HD Kleinloog, ...
British Journal of Clinical Pharmacology 76 (6), 846-857, 2013
592013
Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short-and long-term pharmacokinetics
JAAC Heuberger, Z Guan, OO Oyetayo, L Klumpers, PD Morrison, ...
Clinical pharmacokinetics 54 (2), 209-219, 2015
372015
Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9‐tetrahydrocannabinol‐induced central nervous system and heart rate effects in humans
LE Klumpers, C Roy, G Ferron, S Turpault, F Poitiers, JL Pinquier, ...
British journal of clinical pharmacology 76 (1), 65-77, 2013
232013
A brief background on cannabis: From plant to medical indications
LE Klumpers, DL Thacker
Journal of AOAC International 102 (2), 412-420, 2019
182019
Subjective Effects of Ethanol, Morphine, Δ9-Tetrahydrocannabinol, and Ketamine Following a Pharmacological Challenge Are Related to Functional Brain Connectivity
D Kleinloog, S Rombouts, R Zoethout, L Klumpers, M Niesters, ...
Brain connectivity 5 (10), 641-648, 2015
82015
Pharmacokinetic/pharmaco–dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ9‐tetrahydrocannabinol …
Z Guan, LE Klumpers, OO Oyetayo, J Heuberger, JMA van Gerven, ...
British journal of clinical pharmacology 81 (4), 713-723, 2016
32016
The Therapeutic Potential of Cannabis and the Endocannabinoid System
LE Klumpers, A Hazekamp
Principles and Practice of Botanicals as an Integrative Therapy, 393, 2019
2019
Sex differences in clinical pharmacology and gender differences in society: How to give an emerging industry a head start
L Klumpers
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018
2018
Shaping the bright future of the cannabis industry: Because we can
L Klumpers, D Thacker, K Franson
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018
2018
Does 1+ 1= 3? What science really knows about cannabinoid and terpene effects in humans
L Klumpers, K Franson
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 255, 2018
2018
Namisol: een nieuwe formulering van delta⁹-tetrahydrocannabinol met gunstige farmacokinetiek en veelbelovende farmacodynamische effecten
LE Klumpers, TL Beumer, JGC van Hasselt, A Lipplaa, LB Karger, ...
PW Wetenschappelijk Platform 9 (6), 122-31, 2015
2015
Novel approaches in clinical development of cannabinoid drugs
L Klumpers
Br J Clin Pharmacol 74 (1), 42-53, 2012
2012
TETRAHYDROCANABINOL TABLET NAMISOL®: FIRST IN HUMAN PK, PD AND TOLERABILITY: 20
L Klumpers, T Beumer, L Karger, A Lipplaa, M de Kam, J van Gerven
British Journal of Clinical Pharmacology 72 (5), 2011
2011
First in human trial of an oral tablet with Δ9-THC (Namisol®): P2392
L Klumpers, J van Gerven, T Beumer
European Journal of Neurology 17, 2010
2010
FOCUSED CONFERENCE GROUP: PW03-TARGETING TRP CHANNELS FOR PAIN RELIEF (AND MORE) PHARMACOLOGICAL RESTING STATE-FMRI STUDY USING THC: Paper No.: 2734
L Klumpers, R Soeter, N Khalili-Mahani, S Rombouts, M van Buchem, ...
Basic & Clinical Pharmacology & Toxicology 107, 380-381, 2010
2010
Novel method in pharmacology research: resting state-functional Magnetic Resonance Imaging study using Delta 9-Tetrahydrocannabidiol
L Klumpers, R Soeter, N Khalili-Mahani, M van Buchem, S Rombouts, ...
2010
P. 1. c. 037 Surinabant inhibits the effects of delta 9-tetrahydrocannabinol in a novel tetrahydrocannabinol-challenge test
L Klumpers, C Roy, F Poitiers, S Turpault, JMA van Gerven
European Neuropsychopharmacology, S240-S241, 2008
2008
The system can't perform the operation now. Try again later.
Articles 1–20